ValveXchange announced the appointment of current Chairman of the Board, Mr. John Parrish as Chairman of the Board and Chief Executive Officer and Mr. Duane Knight as Chief Financial Officer. Mr. Larry Blankenship, current President and CEO since the company's establishment as a Delaware C Corporation in late 2007, announced the changes as part of the natural evolution of the company into commercialization. Mr. Parrish has been a Director of the company since 2008 and Chairman of the Board since February 2012. Mr. Duane Knight has served as CFO in several life science companies including Denver Biomedical, Inc.

ValveXchange, Inc. announced the appointment of Mr. Todd D. Campbell as Vice President of Operations. Mr. Campbell has been Sr. Executive Director of Product Development at ValveXchange since 2011, and worked with the company on a consulting basis previously. His appointment as Vice President of Operations reflects the company's continued growth toward commercialization of its novel 2-part heart valve technology. During his 36-year career, Mr. Campbell has specialized in implantable medical devices, with an emphasis on prosthetic heart valves. He has been involved in the research, development, manufacturing and qualification of such devices for companies including Hancock Laboratories (now part of Medtronic), Edwards, Medtronic, St. Jude Medical, Sadra Medical (now part of Boston Scientific), and AorTx (now part of Hansen Medical). As Vice President of Operations, Mr. Campbell is responsible for the facilities and resources necessary for ValveXchange to obtain the components and materials, process the tissue used in its bio-prosthetic heart valves, and to build those valves in clean room conditions under exacting quality requirements. He will also help establish key vendor and other business relationships needed to move the company to commercialization of its heart valve products.

ValveXchange, Inc. announced the appointment of Mr. John Parrish as Chairman of the Board. Mr. Parrish has been a Director of ValveXchange since 2008. His appointment as Chairman reflects the company's continued growth toward commercialization of its novel 2-part heart valve technology. As Chairman, Mr. Parrish will lead fundraising for ValveXchange, working with Mr. Larry Blankenship, the company's President and CEO. He will also help build and support key business relationships as the company moves toward commercialization of its heart valve products.